Cagrilintide 5mg

Description

Cagrilintide is a long-acting, acylated analogue of amylin developed by Novo Nordisk. Amylin is a 37-amino-acid hormone released from pancreatic beta cells together with insulin. Cagrilintide was engineered for once-weekly exposure in clinical studies, compared with the very short half-life of native amylin.

What is Cagrilintide?

Amylin acts on amylin receptors, which are complexes of the calcitonin receptor with receptor activity-modifying proteins (RAMPs). Cagrilintide activates both amylin and calcitonin receptors, a profile described as a dual amylin and calcitonin receptor agonist. Amylin signalling is associated with slowed gastric emptying, suppression of post-meal glucagon and satiety signalling in the brainstem.

Cagrilintide has been tested alone in a phase 2 dose-finding trial and in combination with semaglutide as CagriSema, which has been studied in the phase 3 REDEFINE programme. That combination work makes it a common reference compound for research on amylin and GLP-1 co-agonism.

Research Applications

• Amylin and calcitonin receptor pharmacology
• Gastric emptying and satiety signalling models
• Combination studies with semaglutide
• Comparisons with incretin agonists such as tirzepatide and retatrutide
• Acylation strategies for peptide half-life extension

Product Specifications

• Size: 5mg per vial (also available as Cagrilintide 10mg)
• Form: lyophilized powder in a sealed vial
• Purity: ≥99% (HPLC), manufactured in the USA
• Certificate of Analysis available for each batch
• Storage: store lyophilized product at -20°C, protected from light

For research use only. Not for human or veterinary use. Not a drug, food, or cosmetic. Sold to qualified researchers for in-vitro and laboratory research.